Improving Biopsies using Magnetic Nanoparticles

使用磁性纳米颗粒改善活检

• 批准号: 6932195
• 负责人: EDWARD R FLYNN
• 金额: $ 20.48万
• 依托单位: SENIOR SCIENTIFIC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-20 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6932195
• 关键词: antitumor antibody; bioengineering /biomedical engineering; biomedical equipment development; biopsy; bone marrow; bone marrow neoplasms; clinical biomedical equipment; clinical research; diagnosis quality /standard; human subject; immunomagnetic separation; model design /development; nanotechnology; neoplasm /cancer diagnosis; phantom model; surface coating

DESCRIPTION (provided by applicant): In children with acute lymphomatic leukemia (ALL) and in myelodysplastic syndrome (MDS) with older patients it is extremely important to measure the minimal residual disease (MRD) to monitor the progress of chemotherapy at early stages. Such measurements determine the prognosis, efficacy, and levels of the treatment. The normal method for detection and monitoring is through bone marrow biopsies. Unfortunately, this method, which has not changed in 40 years, requires multiple biopsies to obtain sufficient samples and these must be made at periodic intervals to monitor the treatment. The efficiency and specificity of biopsies can be improved through the use of labeled magnetic nanoparticles and "smart" magnetic collection methods. These antibody-labeled magnetic nanoparticles attach to specific cancer cells in large numbers and the cells are then collected magnetically. This magnetic biopsy technique samples more serum volume requiring fewer biopsies due to the increased efficiency and specificity for particular cell types. The method may also be used for sampling metastatic lesions and may be extended to solid tumors. Following these procedures, magnetic nanoparticles coated with anti-cancer agents may be magnetically concentrated, resulting in direct therapeutic intervention at the cancer site.

描述（由申请人提供）： 在患有急性淋巴白血病（所有）和骨髓增生性综合征（MDS）的儿童中，测量最小残留疾病（MRD）以监测早期化学疗法的进展非常重要。这样的测量确定了治疗的预后，疗效和水平。检测和监测的正常方法是通过骨髓活检。不幸的是，这种方法在40年内没有改变，需要多个活检才能获得足够的样本，必须定期进行这些样本以监测治疗。通过使用标记的磁性纳米颗粒和“智能”磁收集方法，可以提高活检的效率和特异性。这些抗体标记的磁性纳米颗粒大量附着在特定的癌细胞上，然后磁性地收集细胞。由于特定细胞类型的效率和特异性提高，这种磁性活检技术需要更少的血清体积，需要更少的活检。该方法还可以用于取样转移性病变，并可能扩展到实体瘤。遵循这些程序，覆盖有抗癌药物的磁性纳米颗粒可能是磁性浓缩的，从而导致癌症部位直接治疗干预。